JPMorgan raised the firm’s price target on Vera Therapeutics to $39 from $25 and keeps an Overweight rating on the shares. The analyst updated the company’s model following atacicept’s 72-Week phase 2b ORIGIN data earlier this week.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VERA:
- Alpine Immune Sciences price target raised to $33 from $30 at Oppenheimer
- Vera Therapeutics price target raised to $21 from $16 at Wedbush
- Vera Therapeutics price target raised to $34 from $26 at Oppenheimer
- Vera Therapeutics Reports Positive Phase 2b ORIGIN Trial Results
- Vera Therapeutics Announces Promising 72-Week Trial Results